Turnstone Logo.jpg
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
05. November 2024 09:01 ET | Turnstone Biologics Corp.
Turnstone Biologics presents preclinical data highlighting potential for Selected TIL therapy in solid tumors at SITC 2024
Turnstone Logo.jpg
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
08. Mai 2024 09:00 ET | Turnstone Biologics Corp.
Dr. Sammy Farah, Turnstone's President and CEO, to present at the 2024 Bank of America Securities Health Care Conference in Las Vegas, NV.
Turnstone Logo.jpg
Turnstone Biologics to Participate in Upcoming Investor Conferences
21. Februar 2024 06:00 ET | Turnstone Biologics Corp.
Turnstone to present and participate in TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024.
Turnstone Logo.jpg
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
27. November 2023 06:00 ET | Turnstone Biologics Corp.
Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.
Capture_brand and logo.PNG
Morphic to Present at November Investor Conferences
10. November 2023 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Turnstone Logo.jpg
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03. November 2023 06:00 ET | Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
02. Juni 2023 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
07. November 2022 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
03. August 2022 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Upcoming Investor Conferences
11. Mai 2022 09:00 ET | Praxis Precision Medicines, Inc.
BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...